InMode (INMD)
(Delayed Data from NSDQ)
$16.89 USD
+1.37 (8.83%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $16.89 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value D Growth D Momentum C VGM
Brokerage Reports
0 items in cart
InMode Ltd. [INMD]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Company: InMode Ltd.
Industry: Medical - Products
Optimized Entry and Exit Levels for INMD 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: InMode Ltd.
Industry: Medical - Products
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
Terminate Coverage. Acquisition By Sagard Capital For $14.05 Complete
Provider: COLLIERS SECURITIES
Analyst: O'NEIL B
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
INMD Signs Definitive Agreement To Be Acquired By Sagard Capital Partners, LLC. Downgrade to Sell. PT to $14.05.
Provider: COLLIERS SECURITIES
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
INMD: Solid Q4 Results. Vein Center Earnings Poised To Fuel Growth. Affirm Buy And Raising PT To $15.50.
Provider: COLLIERS SECURITIES
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
INMD: Solid Q4 Results. Vein Center Earnings Poised To Fuel Growth. Affirm Buy And $12.50 PT.
Provider: COLLIERS SECURITIES
Analyst: CHAULAGAI D
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
Lowers Outlook Based On Controllable And Uncontrollable Factors. Reducing Estimates For ?10 And ?11. Maintain Buy Rating But Lower Price Target From $16 To $11.50.
Provider: COLLIERS SECURITIES
Analyst: O'NEIL B
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
Q2 EPS Beats By $0.01. Net Income Up 45%. Company Poised To Accelerate Growth Of Both Fertility And Vein Care Businesses. INMD Valued At 3.2x EV/EBITDA On 2010 Forecast. Affirm Buy Rating And $16 Price Target.
Provider: COLLIERS SECURITIES
Analyst: O'NEIL B
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
Company: InMode Ltd.
Industry: Medical - Outpatient and Home Healthcare
Initiating Coverage With A Buy Rating And $16 Price Target
Provider: COLLIERS SECURITIES
Analyst: O'NEIL B
|